Drug General Information
Drug ID
D0VA0J
Former ID
DNC014623
Drug Name
3,4-Dichloro-N-(3,3-diphenyl-allyl)-benzamide
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527275]
Structure
Download
2D MOL

3D MOL

Formula
C22H17Cl2NO
Canonical SMILES
C1=CC=C(C=C1)C(=CCNC(=O)C2=CC(=C(C=C2)Cl)Cl)C3=CC=CC=C3
InChI
1S/C22H17Cl2NO/c23-20-12-11-18(15-21(20)24)22(26)25-14-13-19(16-7-3-1-4-8-16)17-9-5-2-6-10-17/h1-13,15H,14H2,(H,25,26)
InChIKey
OYXWUVAZLKNOAB-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Cholecystokinin receptor type A Target Info Inhibitor [527275]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Pancreatic secretion
Reactome Peptide ligand-binding receptors
G alpha (q) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 527275J Med Chem. 1992 Mar 20;35(6):1042-9.Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
Ref 527275J Med Chem. 1992 Mar 20;35(6):1042-9.Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.